Genvoya and Complera are both once-daily, single-tablet HIV regimens, but they differ in their ingredients, how they work, and in safety/interaction details. Here’s a concise comparison:
- What they are made of
- Genvoya: elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)
- Complera: emtricitabine + rilpivirine + tenofovir disoproxil fumarate (TDF)
- How they work (drug classes)
- Genvoya: integrase strand transfer inhibitor (elvitegravir) boosted by cobicistat
- Complera: non-nucleoside reverse transcriptase inhibitor (rilpivirine) plus two NRTIs (emtricitabine, TDF)
- Dosing and food
- Both are taken once daily with a meal.
- Key safety and tolerability differences
- Kidney and bone safety
- Genvoya uses TAF, which generally has less impact on kidney function and bone density than TDF.
- Complera uses TDF, which can carry a higher risk of kidney effects and bone mineral density loss over time.
- Drug interactions and boosting
- Genvoya contains cobicistat, a booster that can interact with many other medicines (CYP3A4 interactions, acid-reducing medications, certain multivitamins/minerals, etc.). This requires more attention to drug interactions.
- Complera does not use a booster; rilpivirine has its own interaction profile (notably with proton pump inhibitors and some antacid medications; absorption is pH-dependent).
- Baseline viral load considerations
- Complera is not recommended if baseline HIV-1 RNA is very high (e.g., >100,000 copies/mL) because virologic responses can be less robust at higher viral loads.
- Genvoya does not have that same explicit baseline viral-load cutoff in its labeling; treatment decisions still depend on overall resistance and virologic data.
- Other considerations
- Both regimens are generally well tolerated, but rilpivirine can cause mood disturbances or sleep issues in some people, and can cause rash in others.
- Genvoya’s boosting can complicate staying on certain meds (e.g., some anticonvulsants, steroids, statins) due to interactions.
- Practical fit — who might prefer which
- Choose Genvoya if:
- You have concerns about kidney function or bone health (TAF-based).
- You’re on or considering medications with fewer concerns about acid suppression (though there are still many interactions to watch with cobicistat).
- Choose Complera if:
- You don’t have issues with rilpivirine’s interactions (especially with proton pump inhibitors or other acid-suppressing meds).
- You want to avoid boosting with cobicistat (due to possible drug interactions).
- Important: HBV and pregnancy
- Both regimens contain agents active against hepatitis B (emtricitabine and a form of tenofovir). If you have HBV coinfection, discuss specifics with your clinician.
- Pregnancy safety can be a factor; talk with your clinician about which regimen is best if you’re or may become pregnant.
If you’d like, tell me:
- your kidney function (e.g., eGFR)
- any meds you’re taking (especially acid-suppressants, anticonvulsants, steroids, statins)
- your baseline viral load
- any bone health concerns or osteoporosis
- whether you have HBV co-infection or pregnancy considerations
I can tailor the comparison to your situation or help you think through which option a clinician might consider first. This is informational only and not a substitute for medical advice.